Physician profile
Samuel Dey
NPI 1447271242
$2,862.31
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $615 · 2020: $654 · 2021: $669 · 2022: $651 · 2023: $207 · 2024: $65.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $272.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $782.47 | 2019-2024 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $450.50 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $436.51 | 2019-2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $311.72 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $178.23 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $171.75 | 2020-2023 | |
| Vanda Pharmaceuticals INC. | $105.71 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $94.61 | 2022-2023 | Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $70.40 | 2021-2022 | |
| Indivior INC. | $57.83 | 2022-2023 | Perseris |
| Lundbeck LLC | $53.00 | 2019-2020 | |
| Owp Pharmaceuticals, INC. | $31.20 | 2020-2022 | |
| Abbvie INC. | $28.42 | 2021 | |
| Allergan, INC. | $27.80 | 2019 | |
| Axsome Therapeutics, INC. | $24.07 | 2023 | Auvelity |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $19.65 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Dey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.